Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin

Yuxin Xu, Wenyun Zheng, Tianwen Wang, Ping Wang, Ling Zhu, Xingyuan Ma

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

In order to eliminate common side effects to cancer patients and resistance from chemotherapy, a genetic protein TmSm(T34A) was investigated as a sensitizer to doxorubicin. The results indicated TmSm(T34A) enhanced the sensitivity of three breast cancer cell lines to doxorubicin with low dose, and reduced the dose of doxorubicin significantly in contrast to common effective dose. As a synergistic therapy, the TmSm(T34A) also caused strongest apoptotic activity in MCF-7, and the possible molecular mechanisms were explored primarily. The research showed the TmSm(T34A) is promising to be a potential drug in strengthening therapy effects of breast cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)368-372
Number of pages5
JournalBiomedicine and Pharmacotherapy
Volume66
Issue number5
DOIs
StatePublished - Jul 2012

Bibliographical note

Funding Information:
This work was supported by the National Natural Science Foundation (30873190), the National Science Research Project “Significant New Drugs Created” of Eleventh Five-year Plan (2009ZX09103-693) and Key for Fundamental and Interdisciplinary Research of Chinese Ministry (WK0913002).

Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.

Keywords

  • Breast cell lines
  • Chemotherapeutic agent
  • Enhancing sensitivity
  • Genetic protein TmSm(T34A)

Fingerprint Dive into the research topics of 'Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin'. Together they form a unique fingerprint.

Cite this